Back

Economic evaluation of fractional flow reserve-guided versus intravascular ultrasound-guided percutaneous coronary intervention

2 September 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Insights into cardiovascular health: trends, well-being, and economic evaluations Health Economics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Xinyang Hu

The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (China)

7 More presentations in this session

Presentation thumbnail
Nationwide trends in major cardiovascular risk factors in England in the last 2 decades: Health Survey of England 2003-2019
Doctor C. Graham (London, GB)
Abstract Slides Video
Presentation thumbnail
The health and wellbeing of cardiology trainees in the united kingdom
Doctor W. Jenner (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Association between wearable activity trackers usage and levels of physical activity among Athens Medical Society members
Doctor E. Oikonomou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Prevecardio: a single-visit population screening model for detection and prevention of 10-year cardiovascular risk
Doctor J. Flores Soler (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Distinguishing factors in regional variations of TAVI in Japan: the unique role of administrative facility standards compared to other procedures in a high-cost medical care subsidy system
Doctor M. Kanda (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Insights into cardiovascular health: trends, well-being, and economic evaluations

The Event

Event poster

ESC Congress 2024

2 September 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Real world economic evaluation of CT-FFR in patients with suspected coronary artery disease
thumbnail
Congress Session
Intracoronary physiology in percutaneous coronary intervention
thumbnail
Congress Presentation
Clinical outcomes of deferred lesions by IVUS versus FFR-guided treatment decision: the FLAVOUR trial substudy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources